New cancer drug enters first human trials for Tough-to-Treat tumors

NCT ID NCT06716138

Recruiting now Disease control Sponsor: Avistone Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

Summary

This is the first study in people testing a new drug called ANS03 for advanced solid tumors that have specific genetic changes (ROS1 or NTRK). The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it might help shrink tumors. The study will enroll about 96 adults whose cancer has spread or cannot be removed by surgery.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10022, United States
Research Site
RECRUITING

Fuzhou, Fujian, China
Research Site
RECRUITING

Guangzhou, Guangdong, China
Research Site
RECRUITING

Shanghai, Shanghai Municipality, China
Research Site
RECRUITING

Chengdu, Sichuan, China

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED OR METASTATIC SOLID TUMORS HARBORING A ROS1 OR NTRK ALTERATION